Tagged with ART

Algeria Nadia Oka-Bousbia of bioMérieux Algeria discusses the affiliate’s important role within Algeria’s fight against infectious diseases and the training of health managers, difficulties surrounding import restrictions, and the company’s constantly-evolving strategy for the future.   These are exciting times for bioMérieux locally. We understand that earlier this year, your global…

Algeria Karim Harchaoui, country manager of Novartis Algeria, explains the rationale behind the recent restructuring of the Algerian affiliate, the evolution of the company’s local manufacturing footprint, and the strategic importance of Algeria to Novartis within the Africa and Middle East region.   Novartis has undergone an extensive restructuring of the…

Cancer Novartis receives NHS approval for their CAR T-cell therapy to treat leukaemia in children, 10 days after receiving European Commission (EC) approval. “It’s fantastic news for children and young people with this form of leukaemia.” Prof Charles Swanton, Cancer Research UK’s Dubbed as the future of cancer therapy, Kymriah, Novartis’ gene-modifying treatment…

Spain Dr Carlos Macaya received worldwide recognition as a cardiovascular surgeon after he operated on the tender heart of Mother Teresa. Now, as the President of the Spanish Heart Foundation, he wages the war on heart disease in Spain. Spanish women die five per cent more than men from cardiovascular diseases.…

Spain Dr. Carlos Macaya, one of the world’s most renowned cardiologists and president of the Spanish Heart Foundation (FEC), outlines the landscape for cardiovascular disease in Spain. Could you please start by introducing yourself? We understand that you are renowned for having operated on Mother Teresa. “I have participated in over…

Regulatory This week Novartis received approval from the European Commission (EC) for Kymriah, their chimeric antigen receptor T cell (CAR-T) therapy for young people under 25 with cancer of the blood. Leading the way in innovative cancer cures with an unrivalled portfolio of over 20 approved oncology medicines, Novartis is the only company in the…

Metos Rupert Mok, a veteran of the Hong Kong medtech industry, discusses regulatory alignment between Hong Kong and mainland China, opportunities for collaboration, the consumer ‘wearable’ space, and the state of the territory’s start-up ecosystem.   Having worked in the Hong Kong medical device and equipment industry for three decades now,…

UK One notable quirk of the British life sciences ecosystem is the importance of its not-for-profit sector. Indeed, in 2017, UK charities poured GBP 1.6 billion (USD 2.1 billion) into medical research; more than both the Medical Research Council (MRC) and the National Institute for Health Research (NIHR). Simon Gillespie, chief…

Portugal Virgilio Bento, known as ‘V’ amongst his peers, invites readers to discover SWORD Health, an interactive solution for patients undergoing physical recovery programs. In this exclusive interview, he describes how best to tackle future obstacles, the stigmatization endured in the disruptive startup world and the future for one of Portugal’s…

UK Christine (Chris) Fox, VP and general manager UK and Ireland at Amgen, two months into her first country manager position and first time in a role outside of North America, discusses the creation of new, innovative partnership models with stakeholders across the healthcare spectrum, how Amgen is leveraging its biologic…

Pharma What is VR and why should healthcare and pharmaceutical companies take note? VR (Virtual Reality) places the user into a virtual world. VR differs from Augmented Reality (AR), which sets virtual objects against the backdrop of the real world—as in Pokemon Go, the augmented reality smartphone craze of 2016—or simply…

UK With four out of the five NHS bodies, Leeds City Region is strongly anchored in the British life sciences ecosystem. Chair of Leeds City Region Enterprise Partnership, Roger Marsh OBE, highlights what else makes the region special: its great talent, dedication to discovery and ability to build bridges between academia…